Next, we evaluated the correlation between the IRGPs signature and clinical characteristics (age, gender, smoking, EGFR mutation, KARS mutation, radiotherapy, chemotherapy, TNM stage, tumor size, lymph node metastasis, and distant metastasis). This evidence concerns the gene KARS1 and neoplasm.